content_product_pipeline

AGS-003:

mRCC (clear cell) – Ongoing pivotal phase 3 clinical trial; completed enrollment July 2015; overall survival data and primary analysis expected late 2016 or during the 1st half of 2017 pending event rates on study

mRCC (non-clear cell) – Phase 2 clinical trial expected to begin 2nd half 2015

Early stage RCC – Two investigator-initiated phase 2 clinical trials, a neoadjuvant study that has been initiated late 2014 and an adjuvant study expected to initiate during 2nd half of 2015

Other solid tumors – Phase 2 clinical trials planned in bladder and NSCLC to be initiated 2nd half of 2015

AGS-004:

Enrollment in phase 2b clinical trial complete

Two phase 2 clinical trials (one for HIV eradication and one for long-term viral control in pediatric patients). The adult eradication study was initiated in 2014 with the second stage expected to initiate during 2nd half of 2015.

1 Additional pipeline programs include AGS-009 (interferon-alpha neutralizing monoclonal antibody; phase 1a clinical study completed in systemic lupus erythematosus) and AGS-010 (soluble CD-83 recombinant protein; preclinical stage development for transplantation rejection, inflammatory and autoimmune disorders)